Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
When patients shed pounds on semaglutide, their kidney function numbers can look better on paper — but is it real? Two new trial analyses say moderate weight loss on GLP-1s doesn't meaningfully distort creatinine-based eGFR. Still, knowing when to order cystatin C remains a key clinical judgment call for primary care providers.
When a patient loses 25 lbs on semaglutide and their eGFR jumps from 54 to 61 mL/min/1.73 m², it's tempting to celebrate — but is the kidney actually doing better, or is less muscle mass just producing less creatinine? Two new randomized trial analyses tackled this question head-on, and both found reassuring news: moderate weight loss on GLP-1 receptor agonists does not appear to meaningfully inflate creatinine-based eGFR estimates.
The SMART trial (101 adults with CKD, no type 2 diabetes) found that ~10% weight loss on semaglutide didn't correlate with changes in creatinine-based eGFR, cystatin C-based eGFR, or measured GFR. A Danish trial post hoc analysis noted a small creatinine rise with semaglutide — actually the opposite of what muscle-loss artifact would cause — with no significant change in cystatin C or measured GFR.
Key Takeaways:
Why it matters: As GLP-1 use expands in primary care, clinicians need a clear framework for interpreting shifting kidney function numbers. The evidence so far is reassuring, but knowing when to reach for cystatin C — especially in older, frail, or high-stakes patients — can meaningfully change management.
